Nurix Therapeutics to Participate in Upcoming Investor Conferences
03 Abril 2024 - 5:00AM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced that Arthur T. Sands, M.D, Ph.D.,
president and chief executive officer of Nurix, Hans van Houte,
Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s
chief business officer, will participate in the following
conferences in April:
- 23rd Annual Needham Virtual
Healthcare ConferenceFireside chat: Arthur T. Sands, M.D,
Ph.D.Monday, April 8, 2024, from 11:00 – 11:40 a.m. ET
- Stifel 2024 Virtual
Targeted Oncology Forum Fireside chat: Hans van Houte and
Jason Kantor, Ph.D.Tuesday, April 16, 2024, from 1:00 – 1:25 p.m.
ET
- Piper Sandler Spring
Biopharma Symposium (Boston, MA)One-on-one meetings only:
Wednesday, April 17, 2024
Both fireside chats will be webcast live and may be accessed via
links in the Investors section of the Nurix website under Events
and Presentations. The archived webcasts will be available on the
Nurix website for 30 days after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Nurix Therapeutics (NASDAQ:NRIX)
Gráfica de Acción Histórica
De May 2023 a May 2024